Abstract 97P
Background
The search for genetic markers of prognosis seems promising for individualization of treatment programs for patients with brain tumors. The aim of our study is to study the dynamics of the concentration of mutant DNA in the BRAF gene in peripheral blood plasma during and after radiation therapy and compare these data with the effect of treatment.
Methods
Digital droplet PCR (ddPCR) was used to determine the concentration of mutant tumor DNA in 209 blood plasma samples (groups included 57 patients with pons tumors and 29 patients with glioma of the other localization). The samples were obtained before the course of RT, during RT (5-8 fraction) and after RT (27-30 fraction). According to the results of radiation therapy, patients were divided into two groups: 1 – the onset of tumor recurrence less than 6 months after the end of the course of RT; 2 – stabilization of the process for 6 months or more after the end of the course of RT.
Results
A significant increase in the relative concentration of mutant (V600E) DNA of the BRAF gene in peripheral blood at the beginning of the RT course and its decrease by the end of the course in the relapse-free group was shown. No changes or an increase in BRAFV600E levels by the end of the RT course was typical for patients with relapse in the early stages.
Conclusions
Methods of liquid biopsy allow to estimate changes in the amount of mutant (tumor) DNA in peripheral blood plasma in children with brain glioma in RT. Increase in the level of mutant DNA correlates with a more stable effect of the treatment.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract